Q-omics provides the consensus-scored NDUFB5 profile across patient tissues and cancer cell-line models. NDUFB5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, NDUFB5 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, NDUFB5 protein abundance shows 26,742 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, HNSC, and GBM as cancer lineages where NDUFB5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFB5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFB5 survival associations across molecular data types. NDUFB5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFB5 RNA expression–survival associations across cancer types. High NDUFB5 expression shows unfavorable associations in LIHC, HNSC, LUAD and UCEC, but favorable associations in MESO and KIRP. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for NDUFB5 RNA expression.
This table summarizes NDUFB5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFB5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFB5 shows lower tumor expression in THCA and KIRC and higher tumor expression in HNSC, LIHC, LUSC and BRCA. The HNSC box plot shows higher NDUFB5 RNA expression in tumor versus normal tissue (log2 FC = +0.723, t-test p < 0.001).
This table shows molecular features associated with NDUFB5 in patient tissues and cancer cell lines. In patient samples, NDUFB5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFB5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
